Business Description
Cartesian Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US8162121045
Description
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 14.96 | |||||
| Debt-to-Equity | 19.48 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.74 | |||||
| Beneish M-Score | 3.01 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.7 | |||||
| 3-Year EBITDA Growth Rate | -32.1 | |||||
| 3-Year EPS without NRI Growth Rate | -10.2 | |||||
| 3-Year Book Growth Rate | -153.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 44.54 | |||||
| Future 3-5Y Total Revenue Growth Rate | -40.72 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.46 | |||||
| 9-Day RSI | 43.42 | |||||
| 14-Day RSI | 45.56 | |||||
| 6-1 Month Momentum % | -18.1 | |||||
| 12-1 Month Momentum % | -11.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | |||||
| Quick Ratio | 10.7 | |||||
| Cash Ratio | 10.24 | |||||
| Days Sales Outstanding | 75.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.4 | |||||
| Shareholder Yield % | 3.73 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -111.6 | |||||
| Net Margin % | -510.72 | |||||
| FCF Margin % | -100.98 | |||||
| ROA % | -79.52 | |||||
| ROIC % | -24.56 | |||||
| ROC (Joel Greenblatt) % | -1439.14 | |||||
| ROCE % | -96.5 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.04 | |||||
| PB Ratio | 595.81 | |||||
| EV-to-EBIT | -1.06 | |||||
| EV-to-EBITDA | -1.06 | |||||
| EV-to-Revenue | 5.81 | |||||
| EV-to-Forward-Revenue | 23.94 | |||||
| EV-to-FCF | -5.93 | |||||
| Earnings Yield (Greenblatt) % | -94.34 | |||||
| FCF Yield % | -9.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RNAC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cartesian Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 47.938 | ||
| EPS (TTM) ($) | -54.95 | ||
| Beta | 0.49 | ||
| Volatility % | 99.08 | ||
| 14-Day RSI | 45.56 | ||
| 14-Day ATR ($) | 2.077827 | ||
| 20-Day SMA ($) | 20.25925 | ||
| 12-1 Month Momentum % | -11.94 | ||
| 52-Week Range ($) | 11.665 - 41.87 | ||
| Shares Outstanding (Mil) | 25.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cartesian Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cartesian Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cartesian Therapeutics Inc Frequently Asked Questions
What is Cartesian Therapeutics Inc(RNAC)'s stock price today?
The current price of RNAC is $18.47. The 52 week high of RNAC is $41.87 and 52 week low is $11.67.
When is next earnings date of Cartesian Therapeutics Inc(RNAC)?
The next earnings date of Cartesian Therapeutics Inc(RNAC) is 2025-03-07 Est..
Does Cartesian Therapeutics Inc(RNAC) pay dividends? If so, how much?
Cartesian Therapeutics Inc(RNAC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers